LY3361237

DRUG4 trials

Sponsors

Eli Lilly and Company, Stanford University

Conditions

Lupus Erythematosus, SystemicPrimary Sjogren's SyndromePsoriasisSystemic Lupus Erythematosus

Phase 1

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

CompletedNCT03933943

Eli Lilly and CompanyLupus Erythematosus, Systemic

Start: 2019-05-21End: 2021-02-15Updated: 2021-03-04

A Study of LY3361237 in Participants With Psoriasis

CompletedNCT04975295

Eli Lilly and CompanyPsoriasis

Start: 2021-07-27End: 2022-11-29Updated: 2022-12-05

Phase 2

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

TerminatedNCT05123586

Eli Lilly and CompanySystemic Lupus Erythematosus

Start: 2022-03-07End: 2023-12-29Updated: 2025-01-20

Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome

WithdrawnNCT05781451

Stanford UniversityPrimary Sjogren's Syndrome

Start: 2025-01-01End: 2028-01-01Updated: 2024-04-17